Pamidronate Therapy in Children and Adolescents with Secondary Osteoporosis

Jieun Lee, J. Yoon, Y. Lee, J. Lim, C. Shin, S. Yang
{"title":"Pamidronate Therapy in Children and Adolescents with Secondary Osteoporosis","authors":"Jieun Lee, J. Yoon, Y. Lee, J. Lim, C. Shin, S. Yang","doi":"10.6065/JKSPE.2011.16.3.178","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis. Methods: Nine patients (7 males, 2 females, 13.2 ± 2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86 ± 0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle). Results: Underlying diseases were as follows; neurofibromatosis type 1 (n = 2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n = 2), hematologic malignancy (n = 3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91 ± 1.79 to 1.86 ± 1.18, in L1-4 and -3.71 ± 1.83 to -2.53 ± 1.77 for femoral neck; P = 0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P = 0.008; phosphorus, P = 0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47 ± 1.69 years; range, 1.05 to 6.77 years). Conclusion: In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.","PeriodicalId":346664,"journal":{"name":"Journal of Korean Society of Pediatric Endocrinology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Society of Pediatric Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6065/JKSPE.2011.16.3.178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Purpose: The aim of this study was to evaluate the efficacy of pamidronate therapy in children and adolescents with secondary osteoporosis. Methods: Nine patients (7 males, 2 females, 13.2 ± 2.5 years, 10.1-17.4 years) with secondary osteoporosis who had a history of severe bone pain and/or fracture were enrolled. Intravenous pamidronate 1.5 mg/kg (0.5 mg/kg for 3 consecutive days) was given every 6 to 8 weeks for 0.86 ± 0.15 years (6 or 8 cycles). Bone mineral density (BMD) in lumbar spine and femoral neck and their Z-scores were measured before treatment, after the fourth and last cycle (sixth or eighth cycle). Results: Underlying diseases were as follows; neurofibromatosis type 1 (n = 2), epilepsy with/without cerebral palsy (N=2), autoimmune disease treated with steroid (n = 2), hematologic malignancy (n = 3). Bone pain was relieved in most of the patients after the first cycle of treatment, and no more fracture occurred thereafter. There was a significant increase in BMD Z-score of the lumbar spine and femoral neck after the last cycle of therapy, compared to baseline values (from -3.91 ± 1.79 to 1.86 ± 1.18, in L1-4 and -3.71 ± 1.83 to -2.53 ± 1.77 for femoral neck; P = 0.008 and 0.011, respectively). However, there was no significant change in BMD Z-scores between the fourth cycle and the last cycle. Fever developed in 7 out of 9 patients (77.8%), which was relieved by antipyretics. Total serum levels of calcium and phosphorus were significantly decreased (calcium, P = 0.008; phosphorus, P = 0.015) after pamidronate therapy, and three of them experienced symptomatic hypocalcemia during the first cycle. The growth velocity was normal during follow-up periods (mean, 4.47 ± 1.69 years; range, 1.05 to 6.77 years). Conclusion: In conclusion, pamidronate can be administered to the patients with secondary osteoporosis, relieving the symptoms and signs effectively and safely. However, its side effects should be monitored during treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
帕米膦酸钠治疗儿童和青少年继发性骨质疏松症
目的:本研究的目的是评估帕米膦酸盐治疗继发性骨质疏松症的儿童和青少年的疗效。方法:9例继发性骨质疏松患者(男性7例,女性2例,年龄13.2±2.5岁,10.1 ~ 17.4岁)均有严重骨痛和/或骨折病史。帕米膦酸酯静脉注射1.5 mg/kg (0.5 mg/kg,连续3天),每6 ~ 8周一次,共0.86±0.15年(6或8个周期)。治疗前、第4周期、最后1周期(第6、8周期)后测定腰椎、股骨颈骨密度(BMD)及z评分。结果:基础疾病如下;1型神经纤维瘤病(n =2),癫痫伴/不伴脑瘫(n =2),类固醇治疗自身免疫性疾病(n =2),血液系统恶性肿瘤(n = 3)。大多数患者在第一个周期治疗后骨痛减轻,此后不再发生骨折。与基线值相比,最后一个治疗周期后腰椎和股骨颈的BMD z -评分显著增加(L1-4组从-3.91±1.79增加到1.86±1.18,股骨颈从-3.71±1.83增加到-2.53±1.77;P分别= 0.008和0.011)。然而,在第四个周期和最后一个周期之间,BMD z -评分没有显著变化。9例患者中有7例(77.8%)出现发热,经退烧药缓解。血清总钙、磷水平显著降低(钙,P = 0.008;P = 0.015),其中3例在第一个周期出现症状性低钙血症。随访期间生长速度正常(平均4.47±1.69年;范围:1.05至6.77年)。结论:帕米膦酸钠可有效、安全地缓解继发性骨质疏松症患者的症状和体征。然而,在治疗过程中应监测其副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pituitary Hyperplasia Secondary to Hypothyroidism Caused by Hashimoto's Thyroiditis in a Female Adolescent A Case of Idiopathic Hypomagnesemia with Hypocalcemia Presenting as Generalized Tonic-Clonic Seizure A Case of Thyrotoxic Periodic Paralysis in Adolescent with Graves' Disease Body Composition Analysis in Newly Diagnosed Diabetic Adolescent Girls A Single-Arm, Phase III Study to Assess Efficacy and Safety after 6-Month-Treatment of Eutropin™ Inj. (Recombinant Human Growth Hormone) in Prepubertal Children with Short Stature due to Small for Gestational Age
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1